Exploring Experiential Travel Trends and the Impact of Ozempic and GLP1s on Travel Industry

A few months back Skift editor-in-chief Sarah Kopit wrote an article for Skift with the headline "Ozempic Made Obesity Optional. The Travel Industry Isn’t Ready".

On today's episode Seth and Sarah check in on this story and the revolutionary ways in which Ozempic, and other highly effective GLP-1 weight loss medications, are changing how people travel, including which businesses might be potential winners and losers as food and beverage consumption drops and physical experiences become more attainable for more people.

Submit your written or video questions to podcasts@skift.com for a chance to have them aired and answered on a future episode.

Presented by Brand USA

Read more travel news at https://skift.com